KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Receivables (2018 - 2025)

Twist Bioscience (TWST) has disclosed Receivables for 6 consecutive years, with $48.1 million as the latest value for Q2 2023.

  • On a quarterly basis, Receivables rose 4.78% to $48.1 million in Q2 2023 year-over-year; TTM through Jun 2023 was $48.1 million, a 4.78% increase, with the full-year FY2022 number at $45.1 million, up 1830.51% from a year prior.
  • Receivables was $48.1 million for Q2 2023 at Twist Bioscience, down from $48.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $48.5 million in Q1 2023 to a low of $2.0 million in Q3 2021.
  • A 5-year average of $27.1 million and a median of $27.6 million in 2020 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 92.68% in 2021, then soared 2084.7% in 2022.
  • Twist Bioscience's Receivables stood at $13.4 million in 2019, then skyrocketed by 107.18% to $27.8 million in 2020, then fell by 1.36% to $27.4 million in 2021, then skyrocketed by 63.06% to $44.6 million in 2022, then rose by 7.87% to $48.1 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Receivables are $48.1 million (Q2 2023), $48.5 million (Q1 2023), and $44.6 million (Q4 2022).